Savara Inc. Share Price

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
4.08 USD -2.16% Intraday chart for Savara Inc. -13.56% -13.19%
Sales 2024 * - Sales 2025 * 4.9M 385M Capitalization 576M 45.25B
Net income 2024 * -78M -6.12B Net income 2025 * -65M -5.1B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 117 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-10.2 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.16%
1 week-13.56%
Current month-10.92%
1 month-13.01%
3 months-20.31%
6 months+12.40%
Current year-13.19%
More quotes
1 week
4.08
Extreme 4.075
4.50
1 month
4.06
Extreme 4.06
5.31
Current year
4.06
Extreme 4.06
5.70
1 year
2.55
Extreme 2.55
5.70
3 years
1.02
Extreme 1.02
5.70
5 years
0.69
Extreme 0.69
11.42
10 years
0.69
Extreme 0.69
17.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 26/04/17
Director of Finance/CFO 56 26/04/17
Chief Operating Officer 55 12/02/23
Members of the board TitleAgeSince
Director/Board Member 59 26/04/17
Director/Board Member 75 30/09/10
Director/Board Member 56 31/01/09
More insiders
Date Price Change Volume
24/05/24 4.08 -2.16% 718,858
23/05/24 4.17 -3.70% 944,539
22/05/24 4.33 +0.70% 779,740
21/05/24 4.3 +3.12% 888,162
20/05/24 4.17 -6.92% 1,353,270

Delayed Quote Nasdaq, May 24, 2024 at 09:00 pm

More quotes
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.17 USD
Average target price
9 USD
Spread / Average Target
+115.83%
Consensus